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In a previous study, we reported that Alzheimer’s disease-associated presenilin-2 
interacts with a LIM-domain protein, namely, DRAL/FHL2/SLIM3. In this study, we 
investigated whether DRAL modifies the metabolism of the amyloid precursor protein 
(APP). We used small interfering RNA (siRNA) to knockdown DRAL in COS7 and 
HEK293 cells that stably overexpress APP695. We found that the knockdown was 
accompanied by a decrease in the amount of secreted -secretase-cleaved APP and the 
membrane-bound C-terminal fragment C83 and an increase in the amount of secreted 
-amyloid peptide (A from the cells. We also found that in addition to a disintegrin 
and metalloprotease (ADAM)-17, DRAL binds to ADAM-10. Thus, DRAL may be 
involved in the processing of APP through the -secretase pathway.




Alzheimer's disease (AD) is the most common type of senile dementia. It is 
characterized by the progressive formation of insoluble amyloid plaques consisting of 
-amyloid peptides (A), which comprise 40 to 42 amino acids in the brain. A is 
sequentially cleaved from the amyloid precursor protein (APP) by 2 proteolytic 
enzymes, namely, the - and -secretases [5]. In an alternate pathway, APP is cleaved 
within the A-domain (the major site of cleavage is between Lys-16 and Leu-17 in the 
A domain) by -secretase, releasing a large (105-125 kDa) N-terminal ectodomain 
fragment, namely, sAPPfrom the cell surface. A shorter C-terminal transmembrane 
stub, i.e., C83, is further cleaved by -secretase to generate a soluble p3 fragment. Thus, 
the processing of APP by the -secretase pathway precludes the formation of A. In 
many cell types, the activation of protein kinase C (PKC) by the PKC agonist phorbol 
12-myristate 3-acetate (PMA) has been shown to increase sAPP release and reduce the 
secretion of A [1]. Two members of a disintegrin and metalloprotease (ADAM) family 
of proteases, namely, ADAM-10/Kuzbanian and ADAM-17/TACE, have been reported 
to exhibit -secretase activity [1,3,8]. ADAM-10 is considered to be involved in 
constitutive-secretase activity, while ADAM-17 is thought to be involved in 
PMA-stimulated activity. -Secretase consists of at least 4 proteins – presenilin (PS)-1 
or PS-2 at the catalytic core, nicastrin, APH1 and PEN-2 [5]. We previously found that 
PS-2 interacts with DRAL (alias FHL2 or SLIM3), and the overexpression of PS-2 in 
cells resulted in an increase in the amount of PS-2-associated DRAL in the membrane 
fraction [12]. DRAL is a member of a family of 5 proteins containing four and a half 
LIM domains and expressed in various tissues including brain [12]. It participates in 
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various cellular processes, including regulation of cell survival, transcription, and signal 
transduction [6,7,9,11]. Recently, Canault et al. have reported that ADAM-17 interacts 
with DRAL. Under PMA stimulation, DRAL-deficient macrophages had a lower ability 
to release ADAM-17 substrates, tumor necrosis factor receptor-1 and receptor-2 
(TNFR-1 and TNFR-2), when compared with wild-type macrophages [4]. Since 
ADAM-17 is an -secretase candidate of APP, we investigated whether DRAL 
modifies APP metabolism. We used small interfering RNA (siRNA) in 
DRAL-knockdown experiments and found that the knockdown was accompanied by a 
decrease in sAPP secretion and an increase in A secretion. We also found that in 
addition to ADAM-17, DRAL binds to ADAM-10. Thus, DRAL may be involved in the 
processing of APP through the -secretase pathway.
Materials and Methods
Plasmid construction
The entire coding sequences of DRAL, ADAM-10, and ADAM-17 cDNA were 
amplified and cloned into the pFLAG-CMV™-2 (Sigma), pEF6/V5-His (Invitrogen), 
and pcDNA™3.1/Zeo(-) (Invitrogen) vectors, respectively. The cDNA containing the 
last 100 residues of the C termini of APP (C100), and an initiating methionine and the 
last 83 and 89 residues of the APP C terminus (MetC83 and MetC89, respectively) were 
amplified and inserted into the pcDNA™3.1/Zeo(-) vector.
siRNA targeting of the DRAL gene
The siRNA duplexes composed of 21-nucleotide (nt) sense and 21-nt antisense strands 
with a 2-nt 3’ overhang, were designed by using the siRNA user guide of the Tuschl 
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laboratory (http://www.rockefeller.edu/labheads/tuschl/sirna.html). The target 
sequences used in this study are as follows: siRNA B sense: 
5’-gccuguuuccacugcucgctt-3’ and antisense: 5’-gcgagcaguggaaacaggctt-3’; siRNA C 
sense: 5’-gugccaggaaugcaagaagtt-3’ and antisense: 5’-cuucuugcauuccuggcactt-3’; 
siRNA D sense: 5’-cugcuucugugacuuguautt-3’ and antisense: 
5’-auacaagucacagaagcagtt-3’. These sequences are conserved between human and 
COS7 cells. We used control (nonsilencing) siRNA (Qiagen-Xeragon) as a negative 
control.
Transfection for siRNA
The COS7 or HEK293 cells that stably overexpress APP695 (HEK293-APP695 cells) 
[13] were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS). Cells in a 12-well plate were transfected with 
siRNA using the LipofectAmine2000® transfection reagent (Invitrogen) with 2 l/160 
pmol (reagent/siRNA), according to the manufacturer’s instructions. Transfection with 
siRNA involved 2 consecutive rounds in which cells underwent an initial transfection 
(to achieve more complete silencing), and then 2 days later, the cells were replated and 
next day transfected again. Five days after the first transfection, the cells were washed 
with serum-free DMEM and cultured in serum-free DMEM in the absence or presence 
of 30 nM PMA or dimethyl sulfoxide (DMSO) (vehicle) for 6 or 12h; the cells and the 
conditioned medium were then harvested. 
Western blot analysis
The cells were lysed in sodium dodecyl sulfate (SDS)-sample buffer. The collected 
medium was treated with 125 g/ml sodium deoxycholate and 6% (w/v) trichloroacetic 
acid [2]. Proteins were precipitated by centrifugation at 20,800  g for 30 min, and the 
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pellets were washed with 80% ice-cold acetone. Samples were analyzed by 
SDS-polyacrylamide gel electrophoresis (PAGE) and western blot analysis using the 
anti-A mouse monoclonal antibody 6E10(Signet the anti-APP C-terminus 
rabbit polyclonal antibody A8717 (Sigma), the anti-ADAM-17 rabbit polyclonal 
antibody CT (AnaSpec), the anti-ADAM-10 rabbit polyclonal antibody A2851 (Sigma), 
a horseradish peroxidase (HRP)-conjugated anti-V5 mouse monoclonal antibody 
(Invitrogen), an anti-FHL2/DRAL mouse monoclonal antibody 11-134 (MBL), and an 
anti-actin rabbit polyclonal antibody (Sigma). Western blots were visualized and 
quantitatively analyzed by using the luminescent imaging analyzer LAS-1000 
(Fujifilm). The antibody 6E10 does not recognize the -cleaved secreted ectodomain 
APP and p3.
Sandwich enzyme-linked immunosorbent assay for A
The concentration of A in the conditioned medium was measured by a sandwich 
enzyme-linked immunosorbent assay (ELISA) performed using the Signal Select™
Human A40 kit (Biosource), according to the manufacturer’s protocols. The capture 
antibody in this kit is against A1-12 and does not recognize the p3 fragment. The 
resulting values were normalized to the amount of total protein in each cell extract.
Immunoprecipitation
To investigate the interaction of DRAL with ADAM-10 or ADAM-17, COS7 (6-cm 
dish) cells were cotransfected with the indicated expression plasmids using FuGENE 6 
transfection reagent (Roche). Twenty-four hours after the transfection, the cells were 
lysed for 30 min on ice in 800 l of a lysis buffer (50 mM Hepes, pH7.5; 5 mM CaCl2, 
5 mM MgCl2, 50 mM NaCl, 1% NP-40, protease inhibitors CelLytic™M [Sigma], and 
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phosphatase inhibitors [10 mM sodium -glycerophosphate and 1 mM sodium 
orthovanadate]). Insoluble materials were removed by centrifugation (20,800  g for 30 
min). Lysates (400 l) were precleared with protein G-agarose (Roche) and 
immunoprecipitated with mouse anti-FLAG monoclonal antibody M2 (Sigma) and 
protein G-agarose overnight at 4oC. The beads were washed 3 times with lysis buffer, 
and the bound material was eluted by boiling in SDS sample buffer and analyzed by 
SDS-PAGE and western blot analysis.
Results and Discussion
Knockdown of DRAL leads to decreased sAPP release and increased A secretion 
Since the ectopic expression of DRAL has been reported to induce apoptosis in some 
cell lines [11] and DRAL functions as a transcriptional co-activator [6,7,9], we used 
siRNA to knockdown DRAL and examined the effect of this knockdown on the 
metabolism of APP. The transfection of each of the 3 siRNAs against human DRAL 
(siRNA B, siRNA C, and siRNA D) into the COS7 and HEK293-APP695 cells had no 
significant effect on the viability of the cells, as determined by MTS assay (Promega), 
when compared with the viability of mock-transfected and control siRNA transfected 
cells (data not shown). In COS7 cells, different siRNAs against DRAL efficiently 
reduced the DRAL protein level by 92 to 93% (normalized to -actin) as compared with 
control siRNA treatment (Figs. 1 and 2) without significantly altering the expression of 
full-length APP (mature and immature) and actin. The amounts of -secretase-cleaved 
sAPP in the conditioned medium and the C-terminal fragment C83 in the cell lysates 
were detected by western blot analysis (Figs. 1 and 2). -Secretase-cleaved C89 and 
C99 were rarely detected by this analysis (Fig.2). Under the constitutive (unstimulated) 
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condition, the siRNAs against DRAL slightly reduced the amounts of sAPP by 12 to 
22% in the conditioned medium and a single 10-kDa C83 by 10 to 13 % in the cell 
lysates. However, the PMA-stimulated condition, a reduction in endogenous DRAL by 
the siRNA was accompanied by a significant decrease in the amount of sAPP by 28 to 
38% and C83 by 22 to 27% (Figs. 1 and 2). To determine whether DRAL
down-regulation influences the amount of A secretion, each of the 3 DRAL siRNAs 
was introduced in the HEK293-APP695 cells, and the levels of A in the conditioned 
medium were determined by sandwich ELISA (Fig. 3). In the HEK293-APP695 cells, 
DRAL siRNA treatment significantly reduced DRAL levels by 87 to 89% (normalized 
to -actin) as compared with control siRNA treatment (Fig. 3A). While the secretion of 
A was not affected by the transfection of control siRNA, the gene knockdown of 
DRAL by each of the 3 DRAL siRNAs resulted in increased A secretion under the 
PMA-stimulated (by 30 to 34%) and unstimulated (by 21 to 22%) conditions; this 
indicated that DRAL is involved in regulating the production of A under both
conditions, and under the stimulated condition, the amount of A secretion was more 
significantly influenced by DRAL down-regulation. ADAM-17 has been reported to 
interact with DRAL, and under PMA stimulation DRAL-deficient macrophages exhibit 
decreased ability to release ADAM-17 substrates, TNFR-1, and TNFR-2; however, this 
is not observed under the unstimulated condition [4]. Thus, under PMA-stimulated 
condition, DRAL may have considerable effect on -secretase cleavage.
DRAL binds with ADAM-10 in addition to ADAM-17
ADAM-10 and ADAM-17 have been considered to be involved in constitutive 
-secretase activity and PMA-stimulated activity, respectively. Since we observed a 
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slight decrease in sAPP and C83 following the down-regulation of DRAL under the 
unstimulated condition, we examined the interaction between DRAL and ADAM-10 
and ADAM-17. As shown in Fig. 4, V5-tagged ADAM-10 and ADAM-17 were 
co-immunoprecipitated with Flag-tagged DRAL in Flag-tagged DRAL overexpressing 
COS7 cells but not in empty-vector transfected cells. These results suggest that DRAL 
binds with ADAM-10 and ADAM-17 and stimulates -secretase activity for APP.
Influence of DRAL on ADAM-10 and ADAM-17 expression
We investigated whether the down-regulation of DRAL alter the expression of 
ADAM-10 and ADAM-17. The knockdown of DRAL in COS 7 cells did not affect the 
amounts of ADAM-17 and ADAM-10 levels, and there was no difference in the 
unprocessed (proform) or mature (active) forms of either ADAM-17 or ADAM-10 
between lysates from the cells treated with DRAL siRNA and the control siRNA (Fig. 
5). Canault et al. have reported low amounts of ADAM-17 at the surface of wild-type 
mouse macrophages compared to those on the surface of DRAL-deficient macrophages 
and suggested that DRAL is involved in the regulation of the cellular localization of 
ADAM-17 [4]. However, we were unable to determine whether the knockdown of 
DRAL in the COS7 cells influences the cell surface localization of ADAM-10 and 
ADAM-17 (data not shown). A discrepancy in the results may be caused by differences 
between null expression and knockdown or due to the difference between the cell types 
used. We examined the effect of exogenous DRAL expression on the -secretase 
activity of ADAM-10 and ADAM-17. However, the overexpression of DRAL had a 
negligible effect on the release of sAPP and the production of C83 and did not 
enhance the -secretase activity of exogenous ADAM-10 and ADAM-17 expression 
(data not shown). DRAL is an adaptor/docking protein, which interacts with various 
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proteins [6,10]. DRAL may require other factors for the regulation of -secretase 
activity. The results of our study indicate that siRNA-mediated inhibition of 
endogenous DRAL expression is accompanied by a reduction in the -cleavage of APP 
and results in an increase in the amount of A secreted. Thus, our data suggest that 
DRAL regulates APP metabolism by modulating -secretase activity. Since DRAL is 
expressed in the skeletal muscle [12], and overexpression of APP and intracellular 
accumulation of A in vacuolated muscle fibers is considered a central mechanism in 
the pathogenesis of sporadic inclusion body myositis (sIBM) [14], DRAL may be 
involved in APP metabolism in the muscle and the pathogenesis of sIBM.
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Figure legends
Fig. 1. Effect of DRAL siRNA on sAPP secretion. COS7 cells were transfected with 
siRNA indicated in the figure. Five days after the first transfection, the cells were 
treated with 30 nM PMA or DMSO (vehicle) for 6 h. The proteins, concentrated by 
trichloroacetic acid precipitation of the culture medium, and the total cell lysates were 
analyzed using western blot analysis. (A) Western blot analysis of sAPP, full-length 
APP (mature and immature), actin, and DRAL. (B) (C) The amounts of DRAL and 
full-length APP (mature and immature) in the cell lysates (normalized to -actin) were 
determined by western blot analysis. (D) The amounts of sAPP in the conditioned 
medium. The mean of the control siRNA-transfected control in each independent 
experiment was set at 100%. The results are mean  SD of 4 independent experiments. 
*P < 0.05, ***P < 0.005, and ****P < 0.001, compared with the control 
siRNA-transfected cells (paired t test).
Fig. 2. Effect of DRAL siRNA on C83 production. COS7 cells were transfected with 
siRNA indicated in the figure. Five days after the first transfection, the cells were 
treated with 30 nM PMA or DMSO (vehicle) for 6 h. The proteins, concentrated by 
trichloroacetic acid precipitation of the culture medium, and the total cell lysates were 
analyzed by using western blot analysis. (A) Expression levels of C83, actin, and 
DRAL. (B) The amounts of C83 were determined by western blot analysis, and the 
values were normalized to the level of actin in the same sample. The mean of the 
control siRNA-transfected control in each independent experiment was set at 100%. 
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The results are mean  SD of 4 independent experiments. *P < 0.05, **P < 0.01 
compared with the control siRNA-transfected cells (paired t test).
Fig. 3. A sandwich ELISA. HEK293 cells that stably overexpress APP695 were 
transfected with siRNA indicated in the figure. Five days after the first transfection, the 
cells were treated with 30 nM PMA or DMSO (vehicle) for 12 h. A sandwich ELISA 
was performed as described in the Materials and Methods. (A) Effects of DRAL siRNA 
on DRAL levels in HEK293-APP695 cells. The DRAL levels assessed by quantifying 
DRAL in the western blot analysis (normalized to -actin). Transfection with DRAL 
siRNA did not significantly alter the expression of full-length APP, compared with 
control siRNA treatment (data not shown). (B) The quantity of A40 was normalized to 
the protein content of the cells. The mean of the control siRNA-transfected control in 
each independent experiment was set at 100%. The results are mean  SD of 4 
independent experiments. *P < 0.05, **P < 0.01, and ****P < 0.001 compared with the 
control siRNA-transfected cells (paired t test).
Fig. 4. Co-immunoprecipitation of DRAL with ADAM-10 and ADAM-17. Lysates 
(400 l) from the COS7 cells transfected with plasmids indicated in the figure (1 g 
each) were immunoprecipitated using an anti-Flag antibody. The immunoprecipitates 
(IP) and 10 l of each lysate (input) were then analyzed by western blot performed 
using HRP-conjugated anti-V5 (for ADAM-10), anti-ADAM-17, anti-actin, or 
anti-DRAL antibodies.
Fig. 5. Effect of DRAL siRNA on ADAM-10 and ADAM-17 expression. COS7 cells 
were transfected with siRNA indicated in the figure. Five days after the first 
transfection, the cells were treated with 30 nM PMA or DMSO (vehicle) for 6 h. The 
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total cell lysates were analyzed using western blot analysis performed using 
anti-ADAM-10, anti-ADAM-17, anti-actin, and anti-DRAL antibodies. Circles and 
asterisks denote unprocessed (proform) and mature (active) forms of either ADAM-17 
or ADAM-10, respectively.
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